The move by the NHS follows a series of health initiatives launched by the government at the end of last year, one of which was to implement fully "ODM or similar fluid management monitoring technologies" across the health service.
---adds audio interview---
Deltex Medical (LON:DEMG) yesterday hailed as a “step change” a new NHS target for a big increase in patients in the south of England using fluid monitoring systems.
The move by the NHS follows a series of healthinitiatives launched by the government at the end of last year.
One of these was to implement fully "ODM or similar fluid management monitoring technologies" across the health service.
Deltex said its CardioQ-ODM oesophageal Doppler monitor is “by some way the market leading fluid management monitor in surgery in the region".
The targets just announced are for 150 patients per 100,000 in the south of England to be treated with fluid management systems by February and March of next year.
The target rises to 200 patients per 100,000 in the NHS financial year starting 1 April 2013; to 250 patients per 100,000 in the NHS financial year starting 1 April 2014 and to 400 patients per 100,000 in the NHS financial year starting 1 April 2015.
With the population in the region estimated at 13 mln, that would amount to about 54,000 patients per year on fluid management systems by 2015/16.
Ewan Phillips, Deltex Medical's chief executive, said: "Successful implementation of the NHS South of England plan will cause a step change in the market for intra-operative fluid management monitoring in the region in the next two and a half years, with clear potential for either faster or further growth to address the remaining three-quarters of patients where NICE already recommend CardioQ-ODM usage.
In the 2011, CardioQ-ODM was used during surgery on 50 patients a year per 100,000 of population in region covered by the new targets.
The device uses a probe inserted into the oesophagus to monitor a patient’s blood flow during surgery.
It has the potential to save £1,100 per patient treated as they recover more quickly from surgery, have fewer complications and therefore spend less time in hospital.
"CardioQ-ODM has a strong market leadership position in the NHS, is the most widely applicable technology available for major surgery, is the only technology recommended by NICE and is the only technology with an evidence base that shows both improved outcomes for patients and reduced lengths of hospital stay which are the benefits being pursued by the NHS," Phillips added.
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult